YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar, that is now interchangeable [1] Interchangeable designation of YUFLYMA® is supported by positive data from the Phase III interchangeability study in patients with...
Hence then, the article about u s fda grants interchangeable designation to yuflyma adalimumab aaty celltrion s biosimilar to humira adalimumab was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( U.S. FDA grants interchangeable designation to YUFLYMA® (adalimumab-aaty), Celltrion's biosimilar to Humira® (adalimumab) )
Also on site :
- Natural gas line rupture stops traffic on 5 Freeway in Castaic
- 30–35 terrorists on radar: Army steps up counterterror ops in J&K; intense vigil amid 'Chillai Kalan'
- No. 20 Virginia notches first 11-win season by beating 25th-ranked Missouri in the Gator Bowl